Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine

János Szücs, C. Horváth, Éva Kollin, M. Szathmári, István Holló

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Forty-five postmenopausal osteoporotic women with at least one osteoporotic vertebral crush fracture were randomized into three treatment groups. Each patient was on calcitonin, 50 U, on alternate days for 2 weeks monthly (350 U/month), and 500 mg/day oral calcium supplementation. In group II, this therapy was supplemented with phosphate (750 mg/day), and in group III, norandrostenolone decanoate (50 mg/month) was added to the calcitonin + calcium therapy. Bone mineral content, by single photon absorptiometry, of the radius midshaft and distal site (3 cm), as well as the lumbar and metacarpal radiomorphometrical indices were estimated semiannually. The therapeutic trial lasted 36 months except in the phosphate supplementation group, where, due to unfavorable results, treatment was discontinued after 24 months. Calcitonin practically prevented further bone loss for 24 months even in this relatively small and intermittent dosage. Phosphate supplementation was without benefit; however, according to the majority of the examined parameters, combination of calcitonin with the anabolic steroid norandrostenolone decanoate extended efficacy up to 36 months. This latter combination seems to be a promising, relatively inexpensive therapeutic regimen in the treatment of established postmenopausal osteoporosis.

Original languageEnglish
Pages (from-to)7-10
Number of pages4
JournalCalcified Tissue International
Volume50
Issue number1
DOIs
Publication statusPublished - Jan 1992

Fingerprint

Postmenopausal Osteoporosis
Calcitonin
Spine
Decanoates
Nandrolone
Phosphates
Therapeutics
Testosterone Congeners
Calcium
Metacarpal Bones
Photon Absorptiometry
Crush Injuries
Bone Density
Bone and Bones

Keywords

  • Intermittent administration
  • Norandrostenolone decanoate
  • Postmenopausal osteoporosis
  • Small-dose calcitonin

ASJC Scopus subject areas

  • Endocrinology

Cite this

Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine. / Szücs, János; Horváth, C.; Kollin, Éva; Szathmári, M.; Holló, István.

In: Calcified Tissue International, Vol. 50, No. 1, 01.1992, p. 7-10.

Research output: Contribution to journalArticle

@article{f4acfb1fba81438b8dd12ee56f0c76b4,
title = "Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine",
abstract = "Forty-five postmenopausal osteoporotic women with at least one osteoporotic vertebral crush fracture were randomized into three treatment groups. Each patient was on calcitonin, 50 U, on alternate days for 2 weeks monthly (350 U/month), and 500 mg/day oral calcium supplementation. In group II, this therapy was supplemented with phosphate (750 mg/day), and in group III, norandrostenolone decanoate (50 mg/month) was added to the calcitonin + calcium therapy. Bone mineral content, by single photon absorptiometry, of the radius midshaft and distal site (3 cm), as well as the lumbar and metacarpal radiomorphometrical indices were estimated semiannually. The therapeutic trial lasted 36 months except in the phosphate supplementation group, where, due to unfavorable results, treatment was discontinued after 24 months. Calcitonin practically prevented further bone loss for 24 months even in this relatively small and intermittent dosage. Phosphate supplementation was without benefit; however, according to the majority of the examined parameters, combination of calcitonin with the anabolic steroid norandrostenolone decanoate extended efficacy up to 36 months. This latter combination seems to be a promising, relatively inexpensive therapeutic regimen in the treatment of established postmenopausal osteoporosis.",
keywords = "Intermittent administration, Norandrostenolone decanoate, Postmenopausal osteoporosis, Small-dose calcitonin",
author = "J{\'a}nos Sz{\"u}cs and C. Horv{\'a}th and {\'E}va Kollin and M. Szathm{\'a}ri and Istv{\'a}n Holl{\'o}",
year = "1992",
month = "1",
doi = "10.1007/BF00297289",
language = "English",
volume = "50",
pages = "7--10",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine

AU - Szücs, János

AU - Horváth, C.

AU - Kollin, Éva

AU - Szathmári, M.

AU - Holló, István

PY - 1992/1

Y1 - 1992/1

N2 - Forty-five postmenopausal osteoporotic women with at least one osteoporotic vertebral crush fracture were randomized into three treatment groups. Each patient was on calcitonin, 50 U, on alternate days for 2 weeks monthly (350 U/month), and 500 mg/day oral calcium supplementation. In group II, this therapy was supplemented with phosphate (750 mg/day), and in group III, norandrostenolone decanoate (50 mg/month) was added to the calcitonin + calcium therapy. Bone mineral content, by single photon absorptiometry, of the radius midshaft and distal site (3 cm), as well as the lumbar and metacarpal radiomorphometrical indices were estimated semiannually. The therapeutic trial lasted 36 months except in the phosphate supplementation group, where, due to unfavorable results, treatment was discontinued after 24 months. Calcitonin practically prevented further bone loss for 24 months even in this relatively small and intermittent dosage. Phosphate supplementation was without benefit; however, according to the majority of the examined parameters, combination of calcitonin with the anabolic steroid norandrostenolone decanoate extended efficacy up to 36 months. This latter combination seems to be a promising, relatively inexpensive therapeutic regimen in the treatment of established postmenopausal osteoporosis.

AB - Forty-five postmenopausal osteoporotic women with at least one osteoporotic vertebral crush fracture were randomized into three treatment groups. Each patient was on calcitonin, 50 U, on alternate days for 2 weeks monthly (350 U/month), and 500 mg/day oral calcium supplementation. In group II, this therapy was supplemented with phosphate (750 mg/day), and in group III, norandrostenolone decanoate (50 mg/month) was added to the calcitonin + calcium therapy. Bone mineral content, by single photon absorptiometry, of the radius midshaft and distal site (3 cm), as well as the lumbar and metacarpal radiomorphometrical indices were estimated semiannually. The therapeutic trial lasted 36 months except in the phosphate supplementation group, where, due to unfavorable results, treatment was discontinued after 24 months. Calcitonin practically prevented further bone loss for 24 months even in this relatively small and intermittent dosage. Phosphate supplementation was without benefit; however, according to the majority of the examined parameters, combination of calcitonin with the anabolic steroid norandrostenolone decanoate extended efficacy up to 36 months. This latter combination seems to be a promising, relatively inexpensive therapeutic regimen in the treatment of established postmenopausal osteoporosis.

KW - Intermittent administration

KW - Norandrostenolone decanoate

KW - Postmenopausal osteoporosis

KW - Small-dose calcitonin

UR - http://www.scopus.com/inward/record.url?scp=0026502635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026502635&partnerID=8YFLogxK

U2 - 10.1007/BF00297289

DO - 10.1007/BF00297289

M3 - Article

VL - 50

SP - 7

EP - 10

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 1

ER -